Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Nervi

Dermatology Hackettstown, NJ Medical Doctor

NPI 1487859104 CMS profile 339962

108 Bilby Rd Ste 202, Hackettstown, NJ 07840

Open in the dashboard

General payments

$4,357

312 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Nervi of Hackettstown, NJ is reported in the CMS Open Payments database as having received $4,357 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,289 81
2024 General $897 62
2023 General $525 44
2022 General $326 28
2021 General $215 16
2020 General $368 28
2019 General $736 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Nervi
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stephen Nervi were reported at $1,289. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stephen Nervi Dermatology median Middle half National median
2019 $736 $454 $129–$1,240 $163
2020 $368 $235 $81–$756 $114
2021 $215 $377 $108–$1,108 $132
2022 $326 $514 $143–$1,391 $149
2023 $525 $607 $159–$1,674 $160
2024 $897 $751 $204–$1,903 $164
2025 $1,289 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $808 60 payments
  2. E.R. Squibb & Sons, L.L.C. $550 51 payments
  3. LEO Pharma Inc. $462 40 payments
  4. Sun Pharmaceutical Industries Inc. $443 30 payments
  5. Novartis Pharmaceuticals Corporation $242 15 payments
  6. Amgen Inc. $215 13 payments
  7. Janssen Biotech, Inc. $196 6 payments
  8. Galderma Laboratories, L.P. $194 13 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $176 12 payments
  10. Lilly USA, LLC $146 10 payments
  11. Other $923 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,258 311 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. SOTYKTU $561 51 payments
  2. SKYRIZI Immunology $320 22 payments
  3. ILUMYA $236 17 payments
  4. ADBRY $224 20 payments
  5. Otezla $215 13 payments
  6. ENSTILAR $198 17 payments
  7. TREMFYA $196 6 payments
  8. TALTZ $146 10 payments
  9. COSENTYX $140 8 payments
  10. SKYRIZI Immunology $129 11 payments
  11. Other $2,555 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

755

Median for Dermatology: 534

Drug cost

$188,018

Median for Dermatology: $67,151

Branded share of claims

6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 27 $164,242
Pimecrolimus Generic 15 $5,068
Tacrolimus Generic 26 $2,442
Metronidazole Generic 53 $1,982
Ciclopirox Ciclopirox Olamine Brand 18 $1,474
Clobetasol Propionate Generic 32 $1,366
Triamcinolone Acetonide Generic 98 $1,358
Fluorouracil Generic 28 $1,323
Fluocinonide Generic 28 $1,179
Ciclopirox Generic 37 $1,104

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$535,377

Of which drugs: $44,652

Medicare patients

1,241

Average age 76

Services billed

6,635

581 women, 660 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Ischemic heart disease 34%
Diabetes 27%
Chronic kidney disease 21%
Atrial fibrillation 19%
Cancer 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 35 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $180
  • Celgene Corporation $18
$198 — —
SKYRIZI
  • AbbVie, Inc. $116
$116 — —
TREMFYA
  • Janssen Biotech, Inc. $99
$99 — —
Otezla
  • Amgen Inc. $87
$87 27 —
RINVOQ
  • AbbVie, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record